OncoZenge AB (ONCOZ) AI Stock Analysis

• Market Cap: kr65.64M
• Dividend Yield: N/A
• Average Volume (3M): 35.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.41
• Revenue Growth: N/A
• EPS Growth: 20.55%
• Country: SE
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.20
• Shares Outstanding: 12,647,174
• 10 Day Avg. Volume: 29,683
• 30 Day Avg. Volume: 35,930
• PEG Ratio: 0.11
• Price to Book (P/B): 4.41
• Price to Sales (P/S): 43924.69
• P/FCF Ratio: -5.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: kr5.00 ▼(-9.26% Downside)

The score is weighed down primarily by weak financial performance: persistent large losses, substantial ongoing cash burn, and increased leverage that heightens funding and dilution risk despite early revenue formation. Technicals add further pressure with a clear downtrend (below major moving averages and negative MACD). Valuation provides limited support because the negative P/E is driven by losses and there is no dividend yield data.

Positive Factors

Early commercial traction

Sustained movement from near-zero to ~2.8M TTM revenue signals early commercial adoption and validates that the company can generate product receipts. This durable shift reduces binary clinical/R&D risk and provides a base to scale sales and improve operating leverage if growth continues.

Focused product strategy

A single, well‑defined lead asset targeting oral mucositis (a common chemoradiotherapy complication) gives strategic clarity. Focused development can shorten go‑to‑market timelines, simplify regulatory and commercial planning, and make the program more attractive for partnerships or licensing.

Improving cash burn trend

A reduction in cash burn versus prior years indicates emerging operational discipline and progress toward stabilizing cash flows. Structurally, lower negative operating and free cash flow extends runway and gives management more time to execute commercialization or secure less dilutive financing.

Negative Factors

Large ongoing losses

Material and persistent operating losses are a structural constraint: they erode equity, produce negative returns on capital, and force continued external funding. Until profitability approaches, strategic options (R&D, marketing investments, partnerships) remain limited and dilution risk stays elevated.

Weak cash generation

Consistently negative operating and free cash flow (~-7.8M TTM) creates an ongoing reliance on external capital. This structural cash-generation weakness increases funding uncertainty, risks dilution or higher-cost debt, and constrains the company's ability to scale commercial and clinical activities sustainably.

Rising leverage and eroded equity

Higher debt and a sharply reduced equity cushion materially weaken financial flexibility. Increased leverage raises refinancing and covenant risks, elevates funding costs, and narrows the buffer against operating setbacks, making the firm more vulnerable to dilution or restrictive financing terms.

OncoZenge AB Business Overview & Revenue Model

Company Description

OncoZenge AB is a Swedish pharmaceutical company focused on the development and commercialization of innovative treatments for cancer. Leveraging advanced research in oncology, the company aims to address unmet medical needs by offering novel therapeutic solutions that improve patient outcomes. OncoZenge operates within the biotechnology and pharmaceutical sectors, concentrating on the development of proprietary drug formulations and delivery systems designed to enhance the efficacy and safety of cancer therapies.

How the Company Makes Money

OncoZenge AB generates revenue primarily through the development and commercialization of its proprietary cancer treatments. The company may earn income from licensing agreements with other pharmaceutical companies, allowing them to market and distribute OncoZenge's products in various regions. Additionally, OncoZenge might engage in partnerships or collaborations with research institutions and industry peers to co-develop new therapies, potentially leading to shared revenues. The company may also seek funding through grants, research subsidies, or investment from private and public sources to support its research and development activities.

OncoZenge AB Financial Statement Overview

Summary

Financials show early revenue traction (TTM ~2.8M versus near-zero historically), but losses and cash burn remain severe (TTM operating loss ~-8.5M; operating/FCF ~-7.8M). Balance sheet flexibility has weakened with rising debt (~7.5M; debt-to-equity ~0.81) and eroding equity, increasing funding/dilution risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue improved to ~2.8M versus near-zero revenue in prior annual periods, indicating some commercial traction. However, profitability remains very weak: TTM operating loss is ~-8.5M and net loss is ~-8.6M, implying costs are still far above the current revenue base. Margins are deeply negative, and while losses have narrowed versus 2022–2023, the business is not yet close to breakeven.

Balance Sheet

The balance sheet shows a meaningful equity cushion (TTM equity ~9.3M vs. assets ~19.8M), but it has eroded sharply from 2021–2023 levels, reflecting sustained losses. Leverage has increased: total debt is ~7.5M in TTM with debt-to-equity around 0.81 (versus zero debt in prior annual reports), reducing financial flexibility. Returns on equity are strongly negative, underscoring continued value dilution risk if losses persist.

Cash Flow

Cash generation remains the key pressure point: TTM operating cash flow and free cash flow are both about -7.8M, indicating ongoing cash burn to fund operations. Cash burn has improved versus 2022–2023 (less negative), but it is still substantial relative to the company’s scale and continues to require financing support. Overall cash flow quality is weak until operating cash flow meaningfully approaches breakeven.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.83M	1.00K	3.00K	0.00	0.00	0.00
Gross Profit	2.83M	1.00K	3.00K	0.00	0.00	0.00
EBITDA	-8.54M	-8.69M	7.27M	2.77M	-4.89M	-801.00K
Net Income	-8.55M	-8.69M	-15.90M	-46.65M	-3.89M	-636.00K
Balance Sheet
Total Assets	19.84M	11.43M	20.34M	36.89M	85.23M	38.30M
Cash, Cash Equivalents and Short-Term Investments	11.59M	3.86M	12.63M	29.14M	51.22M	10.00M
Total Debt	7.50M	0.00	0.00	0.00	0.00	0.00
Total Liabilities	10.53M	1.48M	1.70M	2.92M	4.90M	9.01M
Stockholders Equity	9.30M	9.95M	18.64M	33.97M	80.32M	29.28M
Cash Flow
Free Cash Flow	-7.78M	-8.76M	-17.08M	-22.08M	-10.12M	-1.00K
Operating Cash Flow	-7.78M	-8.76M	-17.08M	-22.08M	-4.77M	-1.00K
Investing Cash Flow	0.00	0.00	570.00K	0.00	-5.36M	0.00
Financing Cash Flow	13.54M	0.00	0.00	0.00	51.34M	10.00M

OncoZenge AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.51
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ONCOZ, the sentiment is Negative. The current price of 5.51 is below the 20-day moving average (MA) of 5.69, below the 50-day MA of 5.98, and below the 200-day MA of 5.90, indicating a bearish trend. The MACD of -0.26 indicates Positive momentum. The RSI at 39.95 is Neutral, neither overbought nor oversold. The STOCH value of 43.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ONCOZ.

OncoZenge AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SPRINT	49 Neutral	kr171.46M	-5.39	-264.12%	―	-17.80%	-11.96%
EXPRS2	46 Neutral	kr51.97M	-0.79	-88.65%	―	8.46%	11.73%
LIDDS	43 Neutral	kr2.43M	-0.51	-132.58%	―	―	86.26%
MODTX	43 Neutral	kr37.70M	-1.37	-166.94%	―	―	-19.35%
ONCOZ	41 Neutral	kr65.64M	-8.13	-78.79%	―	―	20.55%
LPGO	41 Neutral	kr7.27M	-0.08	-213.85%	―	―	―